Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan, R.O.C.
Division of Cardiac and Vascular Surgery, Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
Anticancer Res. 2020 Dec;40(12):6743-6749. doi: 10.21873/anticanres.14697.
BACKGROUND/AIM: The current study aimed at evaluating the contribution of IL-13 promoter rs1881457 and rs1800925 genotypes to the risk of breast cancer in Taiwan.
A total of 1,232 breast cancer cases and 1,232 age-matched controls were genotyped by typical polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology.
As for IL-13 rs1881457, the rates of AA, AC and CC genotypes were 54.8, 37.9 and 7.3% among the cases, and 53.8, 38.7 and 7.5% among the healthy controls, respectively; there were no statistically significant differences between the two groups (p for trend=0.8889). Also, regarding IL-13 rs1800925, there were no statistically significant differences between the two groups either (p for trend=0.6803). Furthermore, the allelic frequencies for IL-13 rs1881457 and rs1800925 were not differentially distributed between the case and control groups (p=0.6515 and 0.8753, respectively).
The rs1881457 and rs1800925 IL-13 promoter polymorphisms may not serve as breast cancer susceptibility determinants for Taiwanese.
背景/目的：本研究旨在评估白细胞介素 13（IL-13）启动子 rs1881457 和 rs1800925 基因型对台湾地区乳腺癌风险的影响。
采用典型聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法对 1232 例乳腺癌病例和 1232 例年龄匹配的对照进行基因分型。
对于 IL-13 rs1881457，病例组 AA、AC 和 CC 基因型的频率分别为 54.8%、37.9%和 7.3%，对照组分别为 53.8%、38.7%和 7.5%；两组之间无统计学差异（趋势检验 p=0.8889）。同样，对于 IL-13 rs1800925，两组之间也无统计学差异（趋势检验 p=0.6803）。此外，IL-13 rs1881457 和 rs1800925 的等位基因频率在病例组和对照组之间也没有差异（p=0.6515 和 0.8753）。
IL-13 启动子 rs1881457 和 rs1800925 多态性可能不是台湾地区乳腺癌易感性的决定因素。
